A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Clinical trial NCT06988488 · RECRUITING
Trial details
- NCT number
- NCT06988488
- Sponsor
- Celgene
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-07
- Primary completion
- 2027-05-31
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.